ArticleAJNR. American journal of neuroradiology2017
Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous
Article in AJNR. American journal of neuroradiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Magnetic resonance spectroscopy (MRS) for differentiating tumour recurrence from radiation necrosis in treated intra-axial brain tumours.The Cochrane database of systematic reviews · 2026Pooled it
- Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis.AJNR. American journal of neuroradiology · 2025Pooled it
- Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.Radiation oncology (London, England) · 2019Pooled it
- A biopsy-validated study of combined DL-upscaled MRSI and (18F)-FACBC PET for presurgical glioma diagnosis.Frontiers in oncology · 2026Article
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Review
- Review
- The complementary role of MRI and FET PET in high-grade gliomas to differentiate recurrence from radionecrosis.Frontiers in nuclear medicine · 2023Article
- Challenges and opportunities for advanced neuroimaging of glioblastoma.The British journal of radiology · 2023Review
- Editorial: Global excellence in nuclear medicine: North America.Frontiers in medicine · 2023Article
- Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [European journal of nuclear medicine and molecular imaging · 2022Article
- Multiparametric Characterization of Intracranial Gliomas Using Dynamic [18F]FET-PET and Magnetic Resonance Spectroscopy.Diagnostics (Basel, Switzerland) · 2022Article
- Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma.Cancers · 2022Review
- Review
- Combined amino acid PET-MRI for identifying recurrence in post-treatment gliomas: together we grow.European journal of hybrid imaging · 2021Article
- Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.Current oncology reports · 2021Review
- Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.Neuro-oncology · 2020Article
- Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.AJNR. American journal of neuroradiology · 2020Review
- Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model.European journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDifferentiating glioma recurrence from treatment-induced necrosis can be a challenge on conventional imaging. This study aimed to assess the diagnostic performance of each functional MR imaging and PET parameter derived by using simultaneous FDG-PET/MR imaging individually and in combination in the evaluation of suspected glioma recurrence. MATERIALS AND
methodsThirty-five treated glioma patients with 41 enhancing lesions (World Health Organization grade II = 9, III = 13, IV = 19) on MR imaging after an operation followed by radiation therapy and/or chemotherapy formed part of this study. Using PET/MR imaging, we calculated the normalized mean relative CBV, mean ADC, Cho/Cr, and maximum and mean target-to-background ratios. Statistical analysis was performed to determine the diagnostic performance of each parameter by receiver operating characteristic analysis individually and in combination with multivariate receiver operating characteristic analysis for the detection of glioma recurrence. Histopathology or clinicoradiologic follow-up was considered the criterion standard.
resultsOf 35 patients, 25 (30 lesions) were classified as having a recurrence and 10 (11 lesions) patients as having treatment-induced necrosis. Parameters like rCBV
conclusionsSimultaneous PET/MR imaging with FDG offers correlative and synergistic multiparametric assessment of glioma recurrence with increased accuracy and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.